Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
A Phase I/II randomised therapeutic HIV vaccine trial in individuals who started antiretrovirals during primary or chronic infection (EHVA T01/ANRS VRI05)

Proposed period of release:
01/10/2017 to 31/12/2019

Name of the Institute(s) or Company(ies)
Inserm-ANRS, French National Institute for Health and Medical Research-ANRS (France Recherche Nord & Sud- HIV H├ępatites), Paris, France.;

3. Is the same GMO release planned elsewhere in the Community?
Spain; United Kingdom; Italy; Sweden; Czech Republic;

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Modified vaccinia Ankara virus -based anti-HIV vaccine (named MVATG17401 or MVA HIV-B in the clinical trial)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
MVAOrthopoxvirusvaccinia virus---

European Commission administrative information

Consent given by the Member State Competent Authority:
28/02/2019 00:00:00